Mineralys Therapeutics is a technology company.
Mineralys Therapeutics has raised $120.0M across 1 funding round.
Mineralys Therapeutics has raised $120.0M in total across 1 funding round.
Mineralys Therapeutics has raised $120.0M in total across 1 funding round.
Mineralys Therapeutics's investors include Access Biotechnology, Andera Partners, Arix Bioscience, Atlas Venture, Canaan Partners, RA Capital, Versant Ventures, Ysios Capital.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for cardiorenal diseases driven by dysregulated aldosterone, such as hypertension, chronic kidney disease (CKD), and obstructive sleep apnea.[1][2][5] Its lead product candidate, lorundrostat (formerly MLS-101), is a proprietary, orally administered, highly selective aldosterone synthase inhibitor advancing through pivotal Phase 3 trials, including Advance-HTN (topline data expected March 2025) and Launch-HTN (mid-first half 2025).[1][2] The company serves patients with uncontrolled or resistant hypertension and related conditions, addressing unmet needs where current treatments often fail due to aldosterone dysregulation, with ~51 employees and NASDAQ listing (MLYS) since its 2023 IPO.[1][4]
Founded in 2019 and headquartered in Radnor, Pennsylvania, Mineralys Therapeutics (formerly Catalys SC1, Inc., renamed in May 2020) emerged from Catalys Pacific, with Dr. Brian Taylor Slingsby—a serial biotech founder and Catalys Managing Director—as its key founder and Executive Director.[1][3] In 2020, the company licensed lorundrostat from Mitsubishi Tanabe Pharma, which had advanced it through Phase 1; Mineralys then validated its potential in a Phase 2 proof-of-concept study for hypertension.[3] Early traction included initiating Phase 2 trials for lorundrostat in CKD patients and launching pivotal programs for resistant hypertension, led by CEO Jon Congleton and a team with experience from Johnson & Johnson, Portola Pharmaceuticals, and others.[1][3]
Mineralys rides the cardio-renal-metabolic (CRM) trend, where evolving science highlights aldosterone's role in hypertension (affecting ~1.3B globally) and CKD, amid rising demand for precision therapies amid metabolic syndrome epidemics.[5] Timing aligns with post-pandemic focus on unmet needs in resistant hypertension—where 30-50% of patients remain uncontrolled—and aldosterone inhibitors' resurgence after decades of under-exploration.[1][2] Favorable market forces include biotech IPO recovery, regulatory tailwinds for novel oral agents, and partnerships like Mitsubishi Tanabe's licensing, positioning Mineralys to influence the CRM ecosystem by validating aldosterone as a therapeutic axis and potentially enabling combo therapies.[3]
Pivotal topline data from Advance-HTN (March 2025) and Launch-HTN (mid-2025) will be make-or-break, potentially fast-tracking lorundrostat to approval and blockbuster status in resistant hypertension.[2] Trends like AI-driven patient stratification, CRM combo regimens, and aldosterone's expanding role in OSA/heart failure will shape its path, with expansion into CKD Phase 2 signaling pipeline growth.[1][2] Mineralys could evolve from clinical-stage player to CRM leader, humanizing biotech by delivering targeted relief for aldosterone-driven diseases that current standards overlook—echoing its mission to improve outcomes where they're needed most.[5]
Mineralys Therapeutics has raised $120.0M across 1 funding round. Most recently, it raised $120.0M Series B in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $120.0M Series B | Access Biotechnology, Andera Partners, Arix Bioscience, Atlas Venture, Canaan Partners, RA Capital, Versant Ventures, Ysios Capital |